{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:46:12Z","timestamp":1747172772786,"version":"3.40.5"},"reference-count":19,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:sec id=\"S0317167120002012_as1\"><jats:title>Objective:<\/jats:title><jats:p>To describe clinical characteristics of Canadian patients with myelin-oligodendrocyte glycoprotein immunoglobulin-G optic neuritis (MOG-IgG ON).<\/jats:p><\/jats:sec><jats:sec id=\"S0317167120002012_as2\"><jats:title>Methods:<\/jats:title><jats:p>Retrospective observational case series of MOG-IgG seropositive patients with ON referred to tertiary neuro-ophthalmology practices. Outcome measures included clinical characteristics, radiologic findings, and visual outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167120002012_as3\"><jats:title>Results:<\/jats:title><jats:p>Forty-six eyes of 30 patients were included. Twenty-three (76.7%) were women, mean onset age was 40.7 years (range 16\u201377), and most were Caucasian. Seventeen (56.7%) presented with their first ON episode. Sixteen (53.3%) had bilateral eye involvement. Isolated ON without associated neurological symptoms occurred in 90.0%. In 22 patients with acute ON (seen within 1 month of onset), presenting mean visual acuity (VA) was 20\/258 (logMAR 1.11), mean deviation (MD) on Humphrey visual fields was \u221216.90 \u00b1 10.83 dB, and peripapillary retinal nerve fiber layer (RNFL) thickness on ocular coherence tomography (OCT) was 164.23 \u00b1 46.53 um. Orbital magnetic resonance imaging (MRI) within 1 month of symptom onset for 19 patients demonstrated orbital optic nerve enhancement in 11 (57.9%) and perineural enhancement in 11 (57.9%). Brain MRI was normal in 28 (93.3%) patients. Twenty out of 22 patients with acute presentation were treated with high-dose glucocorticoids and 5 with plasma exchange in addition to corticosteroids. Long-term immunosuppression was utilized in 9 (30%) out of all 30 patients. Final VA was 20\/30 (logMAR 0.18), MD was \u22127.17 \u00b1 8.85 dB, and RNFL thickness was 72.15 \u00b1 20.16 um.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167120002012_as4\"><jats:title>Conclusion:<\/jats:title><jats:p>MOG-IgG ON in Canada has a variable presentation with most patients having substantial initial vision loss with good recovery. This is the largest characterization of the disease in Canada to date.<\/jats:p><\/jats:sec>","DOI":"10.1017\/cjn.2020.201","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T05:19:26Z","timestamp":1600060766000},"page":"321-326","source":"Crossref","is-referenced-by-count":0,"title":["Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in Canada"],"prefix":"10.1017","volume":"48","author":[{"given":"Anubhav","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-9152","authenticated-orcid":false,"given":"Jonathan A.","family":"Micieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"S0317167120002012_ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170847"},{"key":"S0317167120002012_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.03.014"},{"key":"S0317167120002012_ref9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sepulveda","year":"2016","journal-title":"J Neurol"},{"key":"S0317167120002012_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.042"},{"key":"S0317167120002012_ref18","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"S0317167120002012_ref16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis: experience of the optic neuritis treatment trial","volume":"109","author":"Beck","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"S0317167120002012_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.020"},{"key":"S0317167120002012_ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00089"},{"key":"S0317167120002012_ref12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"S0317167120002012_ref10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"key":"S0317167120002012_ref2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"S0317167120002012_ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009758"},{"key":"S0317167120002012_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000681"},{"key":"S0317167120002012_ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1144-2"},{"key":"S0317167120002012_ref11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"S0317167120002012_ref8","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s10072-020-04371-z","article-title":"Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis","volume":"41","author":"Jang","year":"2020","journal-title":"Neurol Sci"},{"key":"S0317167120002012_ref15","first-page":"810","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease in a multi-ethnic Canadian cohort","volume":"25","author":"Cross","year":"2019","journal-title":"Mult Scler J"},{"key":"S0317167120002012_ref1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/ICU.0000000000000520","article-title":"Myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis","volume":"29","author":"Chun","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"S0317167120002012_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14089"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167120002012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T06:42:21Z","timestamp":1619505741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167120002012\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0317167120002012"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2020.201","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"type":"print","value":"0317-1671"},{"type":"electronic","value":"2057-0155"}],"subject":[],"published":{"date-parts":[[2020,9,14]]}}}